(Health-NewsWire.Net, October 21, 2021 )
Silent cancer relates to those types of cancer that are undiagnosed in early stages due to the asymptomatic nature of the disease, making it difficult to identify the disease until it progresses to advanced stages.
View full report: https://bit.ly/3aZ2UAa
Technological advancements such as non-invasive radiation therapy are expected to drive the market's growth.
According to the Frontiers Oncology article, in March 2021, curative-intent radiotherapy plays an integral role in treating lung cancer, and therefore improving its therapeutic index is vital. MR guided radiotherapy (MRgRT) systems are the latest technological advancements that may help achieve this aim.
Most MRgRT Therapy delivered to date has been stereotactic body radiation therapy (SBRT) based and includes the Therapy of (ultra-) central tumors. However, there is a move to implement MRgRT as a curative-intent Therapy for inoperable locally advanced NSCLC. Moreover, MRgRT has several potential benefits which are exploited in the lung cancer setting.
The excellent soft-tissue contrast of MRI results in the improved delineation of challenging target volumes, such as those located centrally or close to and invading adjacent structures and OARs. Daily plan adaptation could account for anatomical and physiological changes throughout radiotherapy and thereby has the potential to improve dosimetric accuracy.
Another advantage of MRgRT is the ability to acquire functional imaging to assess response and potentially permit adaptive workflows based on biological information. Thus, from the above statements, the market is expected to drive in the forecast period.
Global Silent Cancer Therapeutics Market By Type
Mouth and Larynx Cancer
Global Silent Cancer Therapeutics Market By Therapy
Global Silent Cancer Therapeutics Market By End user
Ambulatory Surgical Centers
Global Silent Cancer Therapeutics Market - By Region
Middle East & Africa
Download free sample: https://bit.ly/3C4IZeR
The silent cancer therapeutics market is vast with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Carrick Therapeutics, Salarius Pharmaceuticals, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Accuray Incorporated, Varian Medical Systems, and Elekta AB.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the silent cancer therapeutics market globally.
Topic's you may be interested, Platinum Based Cancer Drug Market, Peptide Cancer Vaccine Market, Prostate Cancer Biomarker Market, Follicular Thyroid Cancer Drug Market, Colorectal Cancer Drugs Market
+1 877 441 4866